The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was initiated in 2015. Its goal is to provide an international infrastructure that will enable type 1 diabetes primary prevention trials. These clinical trials are built around programs that identify infants with an elevated genetic risk of developing type 1 diabetes, and will aim to reduce the incidence of clinical diabetes in children.


 The scientists responsible for GPPAD are fighting for a world without type 1 diabetes.



GPPAD’s long-term vision is to stop the trend of an increasing incidence of childhood type 1 diabetes. There must be global action built around a platform that coordinates controlled prevention trials. The GPPAD vision requires the participation and engagement of clinicians, scientists, government, laypersons, and the public at large. Prevention is indeed a global effort, and GPPAD’s success will rely on its ability to integrate and inform all these parties of the need and the means to bring about prevention of a lifelong disease that, in western countries, affects 4 in every 1000 children.


The GPPAD studies focus on preventing beta cell autoimmunity, which is a mistaken reaction of the immune system that causes type 1 diabetes. The preventive treatment should begin when the child is an infant or toddler, as beta-cell autoimmunity often occurs in the child’s first or second year of life. Closely interlinked, multi-regional screening programmes for the early detection of an increased genetic risk of type 1 diabetes in newborns, such as the INGR1D provide an important basis for this.

A genetic test can identify newborns with a 25-fold increase in their risk of developing type 1 diabetes. Families with infants at high risk of the disease are invited to take part in the POInT study aimed at preventing type 1 diabetes autoimmunity. 


GPPAD is supported by the United States Leona M. and Harry B. Helmsley Charitable Trust.

Sites in Europe

GPPAD Research Institutions and Clinics in Europe

Supported by
Secured By miniOrange